Laurus Labs and KRKA Inject ₹1.7 Billion into Joint Venture, Expanding Market Reach

Laurus Labs Ltd and KRKA d.d. are set to boost their joint venture, KRKA Pharma Pvt Ltd, with a combined investment of ₹1.7 billion. Laurus Labs will invest ₹833 million to acquire 83.3 million equity shares, while KRKA will contribute ₹867 million, maintaining their 49:51 ownership ratio. This strategic move aims to fund land acquisition for a new manufacturing facility, cover initial setup costs, and target new markets, including India. The investment, expected to complete by March 31, 2025, aligns with Laurus Labs' long-term growth objectives and strengthens the partnership established in January 2024. This collaboration combines Laurus Labs' research expertise with KRKA's international pharmaceutical experience.

 

Sources: BSE, NSE, Laurus Labs Limited, KRKA